GM-CSF-based treatments in COVID-19: reconciling opposing therapeutic approaches
GM-CSF-based treatments in COVID-19: reconciling opposing therapeutic approaches
复制标题
DOI：
10.1038/s41577-020-0357-7
复制
发表时间：
2020-06-23
影响因子：
100.3
通讯作者：
Hamilton, John A.
中科院分区：
文献类型：
--
作者：
Lang, Frederick M.;Lee, Kevin M-C;Hamilton, John A.
重组粒细胞-巨噬细胞集落刺激因子 (GM-CSF) 以及针对 GM-CSF 或其受体的抗体正在针对 2019 年冠状病毒病 (COVID-19) 的临床试验中进行测试。本观点介绍了 GM-CSF 的多效性功能，并探讨了这些不同方法背后的基本原理。 迫切需要针对 2019 年冠状病毒病 (COVID-19) 的治疗。粒细胞巨噬细胞集落刺激因子（GM-CSF）是一种骨髓生成生长因子和促炎细胞因子，在肺泡巨噬细胞稳态、肺部炎症和免疫疾病中发挥着关键作用。 GM-CSF 的给药和抑制目前正在 COVID-19 临床试验中进行治疗测试。本观点讨论了 GM-CSF 的多效性生物学以及这些对比方法背后的科学优点。
Recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF) as well as antibodies targeted at GM-CSF or its receptor are being tested in clinical trials for coronavirus disease 2019 (COVID-19). This Perspective introduces the pleiotropic functions of GM-CSF and explores the rationale behind these different approaches.Therapeutics against coronavirus disease 2019 (COVID-19) are urgently needed. Granulocyte-macrophage colony-stimulating factor (GM-CSF), a myelopoietic growth factor and pro-inflammatory cytokine, plays a critical role in alveolar macrophage homeostasis, lung inflammation and immunological disease. Both administration and inhibition of GM-CSF are currently being therapeutically tested in COVID-19 clinical trials. This Perspective discusses the pleiotropic biology of GM-CSF and the scientific merits behind these contrasting approaches.